Choreo LLC Buys 3,249 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)

Choreo LLC raised its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 29.9% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 14,100 shares of the company's stock after acquiring an additional 3,249 shares during the period. Choreo LLC's holdings in Prestige Consumer Healthcare were worth $1,091,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. JPMorgan Chase & Co. lifted its stake in shares of Prestige Consumer Healthcare by 3.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 272,255 shares of the company's stock worth $19,630,000 after purchasing an additional 8,533 shares during the period. Geode Capital Management LLC lifted its stake in shares of Prestige Consumer Healthcare by 4.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company's stock worth $95,678,000 after purchasing an additional 50,961 shares during the period. Sequoia Financial Advisors LLC lifted its stake in shares of Prestige Consumer Healthcare by 12.9% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 9,824 shares of the company's stock worth $708,000 after purchasing an additional 1,120 shares during the period. Avior Wealth Management LLC lifted its stake in shares of Prestige Consumer Healthcare by 1,570.7% in the 4th quarter. Avior Wealth Management LLC now owns 8,554 shares of the company's stock worth $668,000 after purchasing an additional 8,042 shares during the period. Finally, Barclays PLC lifted its stake in shares of Prestige Consumer Healthcare by 346.3% in the 3rd quarter. Barclays PLC now owns 92,444 shares of the company's stock worth $6,665,000 after purchasing an additional 71,730 shares during the period. Institutional investors own 99.95% of the company's stock.

Insider Buying and Selling at Prestige Consumer Healthcare

In related news, CEO Ronald M. Lombardi sold 10,875 shares of the firm's stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total value of $898,275.00. Following the completion of the transaction, the chief executive officer now directly owns 320,952 shares of the company's stock, valued at approximately $26,510,635.20. This trade represents a 3.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 1.60% of the company's stock.

Prestige Consumer Healthcare Price Performance

PBH traded down $1.78 during trading on Wednesday, reaching $84.18. 299,858 shares of the company traded hands, compared to its average volume of 319,849. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.10 and a current ratio of 3.68. Prestige Consumer Healthcare Inc. has a 12-month low of $62.35 and a 12-month high of $88.36. The firm has a fifty day simple moving average of $79.30 and a 200 day simple moving average of $75.74. The company has a market cap of $4.16 billion, a P/E ratio of 19.71, a PEG ratio of 2.43 and a beta of 0.50.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $1.22 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. On average, equities analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Wall Street Analysts Forecast Growth

PBH has been the topic of several recent research reports. StockNews.com upgraded shares of Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research note on Friday, January 24th. Sidoti cut shares of Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 target price on the stock. in a research note on Monday, December 9th. Raymond James upgraded shares of Prestige Consumer Healthcare to a "moderate buy" rating in a research note on Thursday, December 19th. Canaccord Genuity Group raised their target price on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a "buy" rating in a research note on Friday, February 7th. Finally, DA Davidson raised their target price on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a "buy" rating in a research note on Friday, February 7th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, Prestige Consumer Healthcare has a consensus rating of "Moderate Buy" and a consensus target price of $92.50.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.